Overview

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
Phase:
PHASE2
Details
Lead Sponsor:
Portal Therapeutics, Inc.
Collaborator:
Celerion